Role of endogenous endothelin in endothelial dysfunction in murine model of systemic sclerosis: Tight skin mice 1

Fundamental and Clinical Pharmacology

Volumn 22, Issue 6, 2008, Pages 649-655

  Richard, Vincent ^a   Solans, Violaine ^a   Favre, Julie ^a   Henry, Jean Paul ^a   Lallemand, Françoise ^a   Thuillez, Christian ^a   Marie, Isabelle ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Endothelin receptor antagonist; Endothelium; Nitric oxide; Prostaglandins; Scleroderma; TSK1+ mice

Indexed keywords

ACETYLCHOLINE; BOSENTAN; ENDOTHELIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROSTAGLANDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; MESENTERIC ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC SCLEROSIS; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ANIMALS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDINS; RECEPTORS, ENDOTHELIN; SCLERODERMA, SYSTEMIC; SULFONAMIDES; VASODILATION; VASODILATOR AGENTS;

EID: 57049135651     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00634.x     Document Type: Article

References (47)

1. Guiducci S., Giacomelli R., Cerinic M.M. Vascular complications of scleroderma. Autoimmun. Rev. (2007) 6 520 523.
2. Kahaleh B. Progress in research into systemic sclerosis. Lancet (2004) 364 561 562.
3. Matucci-Cerinic M., Kahaleh M.B., LeRoy E.C. Vascular involvement in systemic sclerosis, in : Clements P.J., Furst D.E. (Eds Systemic sclerosis, Williams & Wilkins, Baltimore, MD, 1996, pp. 153 174.
4. Denton C.P., Black C.M., Abraham D.J. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat. Clin. Pract. Rheumatol. (2006) 2 134 144.
5. Cailes J., Winter S., du Bois R.M., Evans T.W. Defective endothelially mediated pulmonary vasodilatation in systemic sclerosis. Chest (1998) 114 178 184.
6. Freedman R.R., Girgis R., Mayes M.D. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. J. Rheumatol. (1999) 26 2386 2388.
7. Freedman R.R., Girgis R., Mayes M.D. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. J. Rheumatol. (2001) 28 119 121.
8. Fonseca C., Renzoni E., Sestini P. et al. Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum. (2006) 54 3034 3042.
9. Sfikakis P.P., Papamichael C., Stamatelopoulos K.S. et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. (2007) 56 1985 1993.
10. Shi-Wen X., Denton C.P., Dashwood M.R. et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J. Invest. Dermatol. (2001) 116 417 425.
11. Abraham D., Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther. (2007) 9 (Suppl. 2) S2.
12. Krieg T., Abraham D., Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther. (2007) 9 (Suppl. 2) S4.
13. Shi-Wen X., Kennedy L., Renzoni E.A. et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum. (2007) 56 4189 4194.
14. Shi-Wen X., Renzoni E.A., Kennedy L. et al. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol. (2007) 26 625 632.
15. Vancheeswaran R., Azam A., Black C., Dashwood M.R. Localization of endothelin-1 and its binding sites in scleroderma skin. J. Rheumatol. (1994) 21 1268 1276.
16. Vancheeswaran R., Magoulas T., Efrat G. et al. Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of fibrosis or vascular dysfunction? J. Rheumatol. (1994) 21 1838 1844.
17. Yamane K., Miyauchi T., Suzuki N. et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J. Rheumatol. (1992) 19 1566 1571.
18. Cambrey A.D., Harrison N.K., Dawes K.E. et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am. J. Respir. Cell Mol. Biol. (1994) 11 439 445.
19. Kawaguchi Y., Suzuki K., Hara M. et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann. Rheum. Dis. (1994) 53 506 510.
20. Morelli S., Ferri C., Polettini E. et al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am. J. Med. (1995) 99 255 260.
21. Abraham D.J., Vancheeswaran R., Dashwood M.R. et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. (1997) 151 831 841.
22. Ramirez A., Varga J. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. Treat. Respir. Med. (2004) 3 339 352.
23. Rubin L.J., Badesch D.B., Barst R.J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2002) 346 896 903.
24. Oldfield V., Lyseng-Williamson K.A. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis. Am. J. Cardiovasc. Drugs (2006) 6 189 208.
25. Joglekar A., Tsai F.S., McCloskey D.A., Wilson J.E., Seibold J.R., Riley D.J. Bosentan in pulmonary arterial hypertension secondary to scleroderma. J. Rheumatol. (2006) 33 61 68.
26. Tillon J., Herve F., Chevallier D., Muir J.F., Levesque H., Marie I. Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy. Br. J. Dermatol. (2006) 154 1000 1002.
27. Ramos-Casals M., Brito-Zeron P., Nardi N. et al. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology (Oxford) (2004) 43 1454 1456.
28. Snyder M.J., Jacobs M.R., Grau R.G., Wilkes D.S., Knox K.S. Resolution of severe digital ulceration during a course of bosentan therapy. Ann. Intern. Med. (2005) 142 802 803.
29. Korn J.H., Mayes M., Matucci Cerinic M. et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. (2004) 50 3985 3993.
30. Marie I., Bény J.L. Endothelial dysfunction in murine model of systemic sclerosis: tight-skin mice 1. J. Invest. Dermatol. (2002) 119 1379 1387.
31. Denton C.P., Abraham D.J. Transgenic analysis of scleroderma: understanding key pathogenic events in vivo. Autoimmun. Rev. (2004) 3 285 293.
32. Green M.C., Sweet H.O., Bunker L.E. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am. J. Pathol. (1976) 82 493 512.
33. Osborn T.G., Bashey R.I., Moore T.L., Fischer V.W. Collagenous abnormalities in the heart of the tight-skin mouse. J. Mol. Cell. Cardiol. (1987) 19 581 587.
34. Kasturi K.N., Shibata S., Muryoi T., Bona C.A. Tight-skin mouse an experimental model for scleroderma. Int. Rev. Immunol. (1994) 11 253 271.
35. Weihrauch D., Xu H., Shi Y. et al. Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am. J. Physiol. Heart Circ. Physiol. (2007) 293 H1432 H1441.
36. Mulder P., Richard V., Derumeaux G. et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation (1997) 96 1976 1982.
37. Favre J., Musette P., Douin-Echinard V. et al. Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. (2007) 27 1064 1071.
38. Kaeffer N., Richard V., Thuillez C. Delayed coronary endothelial protection 24 hours after preconditioning: role of free radicals. Circulation (1997) 96 2311 2316.
39. Richard V., Kaeffer N., Tron C., Thuillez C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. Circulation (1994) 89 1254 1261.
40. Kasturi K.N., Hatakeyama A., Spiera H., Bona C.A. Antifibrillarin autoantibodies present in systemic sclerosis and other connective tissue diseases interact with similar epitopes. J. Exp. Med. (1995) 181 1027 1036.
41. Muryoi T., Kasturi K.N., Kafina M.J. et al. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J. Exp. Med. (1992) 175 1103 1109.
42. Shibata S., Muryoi T., Saitoh Y., Brumeanu T.D., Bona C.A., Kasturi K.N. Immunochemical and molecular characterization of anti-RNA polymerase I autoantibodies produced by tight skin mouse. J. Clin. Invest. (1993) 92 984 992.
43. Kasturi K., Shibata S., Muryoi T., Bona C. Tight-skin mouse an experimental model for scleroderma. Int. Rev. Immunol. (1994) 11 253 271.
44. Boulanger C., Luscher T.F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J. Clin. Invest. (1990) 85 587 590.
45. Prins B.A., Hu R.M., Nazario B. et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J. Biol. Chem. (1994) 269 11938 11944.
46. Black S.M., Mata-Greenwood E., Dettman R.W. et al. Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation (2003) 108 1646 1654.
47. Bauer M., Wilkens H., Langer F., Schneider S.O., Lausberg H., Schafers H.J. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation (2002) 105 1034 1036.